CoChat

Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias

Open access
Ferrer, Belen, Asbrock, Nick, Kathuria, Satish, Piomelli, Daniele, Giuffrida, Andrea · 2003 · European Journal of Neuroscience
Cited by 156

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The majority of Parkinson's disease patients undergoing levodopa therapy develop disabling motor complications (dyskinesias) within 10 years of treatment. Stimulation of cannabinoid receptors, the pharmacological target of Δ 9‐tetrahydrocannabinol, is emerging as a promising therapy to alleviate levodopa‐associated dyskinesias. However, the mechanisms underlying this beneficial action remain elusive, as do the effects exerted by levodopa therapy on the endocannabinoid system. Although levodopa is known to cause changes in CB 1 receptor expression in animal models of Parkinson's disease, we have no information on whether this drug alters the brain concentrations of the endocannabinoids anandamide and 2‐arachidonylglycerol. To address this question, we used an isotope dilution assay to measure endocannabinoid levels in the caudate–putamen, globus pallidus and substantia nigra of intact and unilaterally 6‐OHDA‐lesioned rats undergoing acute or chronic treatment with levodopa (50 mg/kg). In intact animals, systemic administration of levodopa increased anandamide concentrations throughout the basal ganglia via activation of dopamine D 1/D 2 receptors. In 6‐OHDA‐lesioned rats, anandamide levels were significantly reduced in the caudate–putamen ipsilateral to the lesion; however, neither acute nor chronic levodopa treatment affected endocannabinoid levels in these animals. In lesioned rats, chronic levodopa produced increasingly severe oro‐lingual involuntary movements which were attenuated by the cannabinoid agonist R(+)‐WIN55,212‐2 (1 mg/kg). This effect was reversed by the CB 1 receptor antagonist rimonabant (SR141716A). These results indicate that a deficiency in endocannabinoid transmission may contribute to levodopa‐induced dyskinesias and that these complications may be alleviated by activation of CB 1 receptors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1460-9568.2003.02896.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 156

Metadata

Authors
Ferrer, B., Asbrock, N., Kathuria, S., Piomelli, D., & Giuffrida, A.
Venue
European Journal of Neuroscience
Publisher
Wiley
Published
2003-09
Volume
18
Issue
6
Pages
1607-1614
ISSN
  • 0953-816X (ISSN-L)
  • 1460-9568
OpenAlex
W2110992486
Cited by
156
References
12
FWCI
4.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias. https://app.cochat.ai/papers/10.1046/j.1460-9568.2003.02896.x
The paper
Ferrer, B., Asbrock, N., Kathuria, S., Piomelli, D., & Giuffrida, A. (2003). Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias. European Journal of Neuroscience. https://doi.org/10.1046/j.1460-9568.2003.02896.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.